The anti-TNF/IL-6 bispecific antibody completely inhibits the inflammatory factor CXCL13 in the arthritis model, and its effect is superior to that of the monoclonal antibody combination (Biesemann et al., 2023). This evidence concerns the gene TNF and arthritic joint disease.